MeAgain Index

MeAgain Index and data featured in

Coming end of January 2027

Q3 2026

Medicare Bridge Launches, and Fall Flavors Arrive

Q2 2026

GLP-1 Pills Take Off, and Classic Meals Get Protein

Q1 2026

Lilly Leads Meds, and Protein Leads Everything Else

Methodology

Three GLP-1 lists, every quarter

Top 10
Leading GLP-1 Meds
The leading GLP-1 meds are evaluated across pricing, insurance coverage, adoption, adherence, real-world weight loss outcomes, quality-of-life improvements, and new research.
Top 10
Trending GLP-1 Products
The fastest-growing and most culturally relevant products for GLP-1 users in the quarter, based on new launches, real-world adoption, social media, AI search and other online conversations.
Top 20
Top GLP-1 Brands
Top GLP-1 brands are ranked based on product diversity & availability, consumer adoption, GLP-1 needs alignment, product ratings & reviews, and online conversations.

How the MeAgain Index is calculated

The MeAgain Index methodology is built on three dimensions: Access, Use and Impact.

Access

01Is it easy to find?: Visibility in web search and AI assistants, sale through proper channels rather than the black market, and a wide range of GLP-1-friendly options.
02Is it easy to understand?: Clear labeling that shows it suits GLP-1 users, such as a high-protein claim. For medications, studies and other information published in terms the everyday consumer can understand and use for decision-making.
03Is it easy to buy?: Price, insurance coverage where it applies, how many pharmacies, stores and online shops sell it, and whether buying it needs a paid membership.

Use

01Do people consider using it?: Interest before people start, measured through social media conversation, AI search and general search volume.
02Do people start using it?: How many people bring a brand or product into their routine or start a medication, from real-world data on the MeAgain platform and third-party sources.
03Do people keep using it?: How many keep using or taking it, from repeat logging on the MeAgain platform and third-party data such as prescription refills.

Impact

01Does it improve health?: Health results such as weight loss among the people using it, alongside published third-party studies.
02Does it improve daily life?: Side effects, tone and sentiment from users on the MeAgain platform, case studies and third-party studies of wider effects, such as drinking less alcohol.
03Do people recommend it?: Posts and comments on Reddit, TikTok, Instagram and YouTube, plus ratings, reviews and polls on the MeAgain platform.

How to read the rankings

+3: Places up since last quarter
−2: Places down since last quarter
–: Same place as last quarter
New: New to the list this quarter
Dropped out: On last quarter's list, not on this one
Seasonal: A seasonal product

Unique combination of proprietary data and external sources

Depending on the signal, the MeAgain Index draws on proprietary data from hundreds of thousands of members on the MeAgain platform and tens of millions of data points. This is connected with external data sources and custom-built in-house tools that track the wider GLP-1 market, to give the most comprehensive view of GLP-1 use available. Figures from the MeAgain platform are adjusted for the growth of our member base.

How often the MeAgain Index is published

The MeAgain Index is published every quarter. Each dimension is scored and weighted using a proprietary model built by the MeAgain data team. The exact formula is not disclosed.

A living methodology

We expect the MeAgain Index to keep evolving as the MeAgain platform grows and GLP-1 treatment continues to change, and we will add new data sources once we are confident they are reliable enough to include. All figures are aggregated and anonymized, and we never show any individual's data.

For more information about the MeAgain Index please contact index@meagain.com

MeAgain Index

Three GLP-1 lists, every quarter

Leading GLP-1 Meds

Trending GLP-1 Products

Top GLP-1 Brands